Product class:
|
Medicinal product with marketing authorization
|
Medicinal product class:
|
Veterinary medicine
|
Name of medicinal product:
|
Arti-Cell Forte
|
Active substances:
|
|
ATC code:
|
QM09AX90
|
Dosage form:
|
suspension for injection
|
Strength:
|
|
Legal status for supply*:
|
Subject to medicinal prescription
|
Summary of product characteristics (SPC):
|
|
Package information leaflet (PIL):
|
EST
|
Labelling:
|
|
Indication:
|
Reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
|
Safety features:
|
No
|
Marketing authorization holder:
|
Boehringer Ingelheim Vetmedica GmbH
|
Marketing authorization number:
|
EU/2/18/228
|
Marketing authorization issued on:
|
April 2, 2019
|
Marketing authorization expires on:
|
April 2, 2024
|
Marketing authorization procedure type:
|
Centralised
|
Assessment report:
|
|
Package code
|
Name of medicinal product
|
Dosage form
|
Package
|
Legal status
|
Reimbursements
|
Reference price
|
Last imported
|
PƤritolumaa
|
Additional information
|
1792537
|
Arti-Cell Forte
|
suspension for injection
|
1annus 1TK
|
Prescription
|
|
|
|
|
|
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription
You can download Acrobat Reader fromhere